Craig-Hallum raised the firm’s price target on Celcuity to $25 from $20 and keeps a Buy rating on the shares. The firm says Celcuity’s Q4 marked another quarter of progress – as timelines remained on track with previous commentary and key readout catalysts continued to draw closer. Geda’s top-line data for the VIKTORIA-1 trial was, once again, reiterated to read out the second half of 2024 for the PIK3CA wild-type sub-group and first half of 2025 for the PIK3CA mutated sub-group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
- CELC Upcoming Earnings Report: What to Expect?
- Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
- Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
